Barinthus Biotherapeutics plc
BRNS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $48 | $142 | $88 | $413 |
| - Cash | $111 | $142 | $194 | $214 |
| + Debt | $12 | $13 | $9 | $7 |
| Enterprise Value | -$51 | $13 | -$98 | $206 |
| Revenue | $15 | $1 | $45 | $0 |
| % Growth | 1,766.5% | -98.2% | 16,580.2% | – |
| Gross Profit | $15 | $1 | $45 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$55 | -$71 | $5 | -$48 |
| % Margin | -369.9% | -8,861% | 11.6% | -17,861.9% |
| Net Income | -$61 | -$73 | $5 | -$51 |
| % Margin | -408% | -9,145.5% | 11.9% | -18,979.5% |
| EPS Diluted | -1.55 | -1.91 | 0.14 | -1.37 |
| % Growth | 18.8% | -1,464.3% | 110.2% | – |
| Operating Cash Flow | -$29 | -$51 | -$14 | -$33 |
| Capital Expenditures | -$1 | -$5 | -$6 | -$1 |
| Free Cash Flow | -$30 | -$56 | -$21 | -$34 |